Amgen Inc.

Other

Zhulun Wang

Xiaoshan Min

Ian Nevin Foltz

Donghui Shi

Kenneth William Walker

Gunasekaran Kannan

Agnes Eva Hamburger

Neeraj Jagdish Agrawal

Murielle M Veniant-Ellison

Chadwick Terence King

Randal Robert Ketchem

Jackie Zeqi Sheng

Ai Ching Lim

Dirk E Smith

Yi Lin Zhang

YuMei Xiong

Jie Tang

Rutilio Clark

Darren L Bates

Michael R Comeau

Grant Shimamoto

Christopher Murawsky

Mark E Daris

David J Lloyd

Marissa Mock

Jay Patrick Powers

Daqing Sun

Derek Evan Piper

Bryan D Lemon

Cen Xu

Kevin Graham

Junming Yie

Christopher Mohr

Brandon C P Clavette

Irwin Chen

Yi Zhang

Jinghong Wang

Shu-yin Ho

Glenn N Sivits, Jr

Renee Komorowski

Sarah Elizabeth Lively

Andrew Smith

Alexander David Frenkel

Craig Tomooka

Khaled M K Z Ali

Shunsuke Takenaka

Yang Li

Jiangchun Xu

Richard Jeffrey Armitage

Dustin L McMinn

Xuelei Yan

Yosup Rew

Mark Leo Michaels

Felix Gonzalez Lopez De Turiso

William C Fanslow, Iii

Jacob A Kaizerman

Michael R Degraffenreid

Pavel V Bondarenko

Jason Charles O'Neill

Lisa D Julian

Michelle Blake

Mark Edward Tometsko

Todd Hager

Aiko Umeda

Athena Sudom

Xinle Wu

Daren Bates

Jason Charles O'neill

Yumei Xiong

Richard J Armitage

Ian Foltz

Fernando Garces

Dustin Mcminn

Shunseke Takenaka

Khaled MKZ Ali

Iii William C Fanslow

Jacob Kaizerman

Michael Degraffenreid

William C Iii

Bram Estes

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

ST2 antigen binding proteins

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

Anti-PD-1 antibodies and methods of treatment

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

PAC1 antibodies and uses thereof

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.

BCMA antigen binding proteins

Growing community of inventors

Palo Alto, CA, United States of America

Zhulun Wang